OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd reported a decrease in revenues by 12.7% and an increase in losses by 9.1% for the fiscal year ended June 30, 2024, with a notable decline in net tangible assets per share from 0.50 to 0.14 cents. No dividends were issued during this period, and the company experienced the de-registration of OncoSil Medical Singapore Pte Ltd. The financial statements are currently under audit, with an unmodified opinion anticipated despite concerns about the company’s ability to continue as a going concern.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.